Reviewing Aethlon Medical (AEMD) & Its Competitors

Share on StockTwits

Aethlon Medical (NASDAQ: AEMD) is one of 23 public companies in the “Analytical instruments” industry, but how does it contrast to its competitors? We will compare Aethlon Medical to related companies based on the strength of its risk, institutional ownership, analyst recommendations, dividends, profitability, earnings and valuation.

Valuation & Earnings

This table compares Aethlon Medical and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aethlon Medical $150,000.00 -$5.67 million -2.20
Aethlon Medical Competitors $1.08 billion $109.59 million 25.08

Aethlon Medical’s competitors have higher revenue and earnings than Aethlon Medical. Aethlon Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aethlon Medical and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aethlon Medical 0 0 1 0 3.00
Aethlon Medical Competitors 121 746 1100 53 2.54

Aethlon Medical currently has a consensus target price of $3.00, indicating a potential upside of 197.03%. As a group, “Analytical instruments” companies have a potential upside of 2.50%. Given Aethlon Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Aethlon Medical is more favorable than its competitors.

Insider and Institutional Ownership

7.4% of Aethlon Medical shares are held by institutional investors. Comparatively, 62.9% of shares of all “Analytical instruments” companies are held by institutional investors. 6.6% of Aethlon Medical shares are held by insiders. Comparatively, 14.7% of shares of all “Analytical instruments” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Aethlon Medical and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aethlon Medical N/A -126.58% -96.36%
Aethlon Medical Competitors -246.84% -38.21% -16.02%

Volatility & Risk

Aethlon Medical has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Aethlon Medical’s competitors have a beta of 1.20, suggesting that their average stock price is 20% more volatile than the S&P 500.

Summary

Aethlon Medical competitors beat Aethlon Medical on 8 of the 13 factors compared.

About Aethlon Medical

Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. The company was founded in 1991 and is based in San Diego, California.

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.